Therapeutic goods administration grants provisional approval for moderna's covid-19 vaccine in children aged six months to five years

Announcement follows recent authorization of the company's mrna covid-19 vaccine in argentina, canada, israel, the us, and taiwan for active immunization to prevent covid-19 caused by sars-cov-2 in children aged 6 months to five years cambridge, ma / accesswire / july 18, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the therapeutic goods administration (tga) in australia has granted provisional registration for the use of moderna's mrna covid-19 vaccine, spikevax, in a two-dose series of 25 Μg per dose for active immunization to prevent covid-19 caused by sars-cov-2 in children aged 6 months to 5 years. until now, children under six were the only age group not eligible for vaccination against covid-19 in australia.
MRNA Ratings Summary
MRNA Quant Ranking